Spiration raises $6.5 million
By Seattle Business Magazine April 30, 2010
We’ve been keeping an eye on Spiration, the Redmond-based biotech company that developed the IBV valve system, the first medical device approved for use in the lung. This week, Spiration raised $6.5 million to fund clinical studies for the device. The IBV valve system is approved for the treatment of emphysema in Europe, but is…
We’ve been keeping an eye on Spiration, the Redmond-based biotech company that developed the IBV valve system, the first medical device approved for use in the lung. This week, Spiration raised $6.5 million to fund clinical studies for the device. The IBV valve system is approved for the treatment of emphysema in Europe, but is still undergoing clinical trials in the U.S.
The June issue of Seattle Business Magazine will feature a full article on Spiration and the IBV valve system. Stay tuned.